CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Imago Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Imago Biosciences Inc
303 Twin Dolphin Drive, 6Th Floor
Phone: (415) 529-5055p:415 529-5055 REDWOOD CITY, CA  94065  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 1/11/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Imago BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It focuses on providing treatment for patients with cancer and bone marrow diseases. The Company’s lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company’s product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The Company also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. It tests bomedemstat in mouse models of MPNs as a single agent.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202212/31/2021YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Dennis J.Henner 70 10/1/2014 10/1/2014
Chief Executive Officer, Director Hugh Y.Rienhoff 69 3/1/2012 3/1/2012
Chief Financial Officer Laura G.Eichorn 50 3/23/2022 3/1/2012
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 41 (As of 9/30/2022)
Outstanding Shares: 33,822,201 (As of 11/2/2022)
Shareholders: 25
Stock Exchange: NASD
Federal Tax Id: 454915810
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, June 26, 2024